Navigation Links
Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim Analysis; Plans Follow-On Clinical Trial Studying Post-Herpetic Neuralgia (PHN)
Date:9/9/2008

SAN FRANCISCO, Sept. 9 /PRNewswire/ -- Epiphany Biosciences, Inc. today announced that a Phase 2b dose-ranging study to evaluate the safety, efficacy, and tolerability of the company's lead compound, valomaciclovir (EPB-348) in patients with acute herpes zoster infection (shingles), will continue as originally designed following an interim analysis.

Fred Volinsky, MD, Epiphany's CEO said, "We are pleased with the progress of this clinical trial and look forward to the final data. If successful, valomaciclovir will mark an advance in the treatment of herpes zoster which affects more than two million people annually around the globe. As the world population ages, it is expected that the incidence of this disease will grow significantly, especially in lieu of the lackluster response to vaccines in this area. We look to valomaciclovir to enhance the treatment experience by being the first once-daily therapy for shingles." The Phase 2b study is being conducted at sites throughout North America and uses an active comparator, valacyclovir. Outcomes assessed include various efficacy parameters including time to vesicular resolution and safety data collection.

In addition to the Phase 2b zoster study, valomaciclovir will also be studied in a separate Phase 2 clinical trial as a therapy in managing the most severe sequelae of a herpes-zoster infection, post-herpetic neuralgia or PHN. "The spectrum of disease caused by herpes viruses is underappreciated but a disease like shingles can have a profound impact on the quality-of-life of patients, many times leading to severe pain syndromes that could have a viral etiology. We look forward to examining the clinical utility of valomaciclovir in multiple conditions associated with herpes viruses and plan to maximize the broad-acting antiviral profile of this drug," reported Brian Murphy, MD, Chief Medical Officer of Epiphany.

In addition to the studies directed at herpes zoster, valomaciclovir is also being studied in a Phase 2 trial of acute infectious mononucleosis, a syndrome commonly seen in adolescents and young adults, caused by Epstein-Barr virus (EBV), also a member of the herpes virus family. "Further studies of valomaciclovir outside herpes zoster are warranted and we plan to examine uses of this drug in major diseases associated with EBV," commented Dr. Murphy.

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr virus (EBV) and hepatitis C virus (HCV).

Fred Volinsky, CEO

415 765 7193


'/>"/>
SOURCE Epiphany Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
2. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing ... children, today reported financial results for the fourth ... and provided an update on its corporate activities. ... during the fourth quarter of 2016 through the ... study, and with our lead development candidate, PRX-OTC, ...
(Date:3/24/2017)... Oregon and PUNE, India , March 24, 2017 /PRNewswire/ ... 2015, and is estimated to reach $2,614 million by 2022, Globally, registering a CAGR ... to generate the highest revenue, and is projected to dominate the market during the ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the ... Conformity for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment ... specifications such as ANSI, ISO and proven test methods used in the field ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... it can quickly sideline athletes. A type of groin injury, it occurs when ... leads to serious, intense pain in and around the lower torso, as well ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... researchers to pursue the recent RNA methylation “gold rush” with their established portfolio ... the newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received ...
(Date:3/27/2017)... ... March 27, 2017 , ... Janet Schloz is still in shock after receiving a $2,500 Academic ... in a long time,” she said. , She thinks the coming week is going to ... thought I would have to help my students.” , The award will allow the 4th ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... industry. Conventional sodium testing methods are complicated and require expert user knowledge. In ... new analytical method dedicated to the simplified, yet highly accurate, determination of sodium. ...
Breaking Medicine News(10 mins):